Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN-115314 Ointment in Mild to Moderate Atopic Dermatitis Adult Patients
NCT07073677Phase 2Recruiting
- Sponsor
- HK inno.N Corporation
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CJ-15314 in atopic dermatitis (AD) (3 arms), sponsored by HK inno.N Corporation. Primary endpoint: Change rate in Eczema Area and Severity Index at 4 weeks. Started Aug 2025; status: recruiting.
02
Drugs
CJ-15314
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07073677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07073677.